Mr. K Bhawaj Raj — MRI + Clinical Summary

What the MRI Report Tells Us

Pituitary Region — Reassuring

• Height 7.2 mm (normal for age)
• Adeno- and neurohypophysis: normal signal
• Hypothalamus, pituitary stalk, sella, parasellar region: all normal
• Optic chiasma: normal

Skull/Brain — Active Disease Findings ⚠️

"Few ill-defined heterogeneously enhancing lytic lesions of variable sizes causing erosion of cranium involving right frontal & occipital bones seen infiltrating into adjacent soft tissue planes."

• Right occipital bone: largest lesion ~23.2 × 11.8 mm — actively enhancing, with soft tissue infiltration
• Right frontal bone: additional lytic lesion
• Post-procedural soft tissue changes in left frontal & high parietal region (prior surgery/procedure site)
• Cerebral parenchyma, brainstem, ventricles: normal — no CNS parenchymal involvement

Clinical Significance: This Is Active Multifocal LCH

• Multiple skull lesions = multifocal bone disease
• Central DI = special site (CNial-facial bones with intracranial extension / hypothalamic-pituitary involvement)

Can He Undergo Chemotherapy?

Why Systemic Chemotherapy Is Indicated

"More extensive disease requires systemic therapy, which typically begins with vinblastine and prednisone under expert supervision." "Current standard of care for multisystem disease is vinblastine and prednisone induction followed by 12 months of continued therapy."

Standard First-Line Regimen

• Vinblastine + Prednisone — the standard induction regimen
• Duration: induction phase followed by 12 months of maintenance therapy (reduces relapse from 54% → 37%)
• If he fails first-line, second-line options include cladribine, cytarabine, clofarabine

BRAF Testing — Critical Before Starting

• BRAF V600E positive → may respond to vemurafenib or dabrafenib (RAF inhibitors)
• BRAF wild-type with MAPK pathway mutations → MEK inhibitors (e.g., cobimetinib — FDA approved for histiocytic neoplasms)
• Positive BRAF status indicates higher-risk disease and possible resistance to vinblastine

Considerations for Raj Specifically

Absolute Precautions

1. Monitor serum sodium frequently throughout chemotherapy — Raj's inability to regulate free water (DI on DDAVP) puts him at extreme risk for hyponatremia from SIADH-inducing chemo agents
2. Use isotonic IV fluids during chemotherapy infusions — never hypotonic fluids
3. Do not co-administer DDAVP + aggressive IV hydration without sodium monitoring
4. Recheck bone marrow, liver, spleen status (to classify as low-risk vs. high-risk multisystem) before starting

Bottom Line

Why the Pituitary Looks Normal But DI Persists

The Core Anatomy: DI Is a Hypothalamic Disease, Not Just a Pituitary Disease

1. Synthesized in the supraoptic and paraventricular nuclei of the hypothalamus
2. Transported down axons through the pituitary stalk
3. Stored and released from the posterior pituitary (neurohypophysis)

What LCH Does to This Axis

• LCH lesional cells (CD1a+, BRAF V600E mutated histiocytes) infiltrate the infundibulum (stalk) and hypothalamic floor
• This causes granulomatous destruction of the axons carrying AVP
• The posterior pituitary, deprived of AVP from above, becomes non-functional
• On T1 MRI, the normal posterior pituitary bright spot (which represents stored AVP in secretory granules) disappears — this is the classic early MRI finding of central DI

Why the Current MRI Looks "Normal"

1. The Damage Has Already Occurred — The Active Phase Is Over

"With earlier diagnosis and effective chemotherapy, the contemporary incidence of diabetes insipidus has been reduced to 7 to 20%."

2. The Posterior Pituitary Bright Spot Is Absent (Look Carefully)

3. The "Top of the Stalk" Rule

Why LCH-Related DI Is Almost Always Permanent

• The granulomatous infiltrate destroys the magnocellular neurons themselves in the hypothalamus
• These neurons do not regenerate
• Even after treating the LCH with chemotherapy, the DI does not reverse — it is a permanent sequel
• This is why Raj will need DDAVP lifelong, regardless of how well the LCH is treated

Summary

PET-CT Report — Clinical Correlation & Next Steps

What the PET-CT Is Telling Us

The Good News — No Visceral/Systemic Spread

• Brain parenchyma: normal
• Lungs: no nodules, no FDG-avid lesions
• Liver, spleen, pancreas: unremarkable
• Bone marrow (indirect assessment): no diffuse uptake
• No lymphadenopathy anywhere
• Abdomen/pelvis: completely clear

The Critical Finding — Disease Reactivation ⚠️

"New onset hypermetabolic lytic lesions in skull (right frontal & left posterior parietal bones) and left 3rd rib. Likely recurrent disease."

Clinical Correlation: What This Means for Raj

"Reactivation occurs in 20–50% of patients. Low-risk patients are those who initially had low-risk multisystem LCH (no risk organ involvement or multifocal bone disease)."

Next Steps — Action Plan

STEP 1 — Histopathology Correlation (Urgent — as the radiologist recommends)

1. Confirm active LCH (vs. reactive change, infection, or secondary malignancy — rare but important)
2. Send tissue for BRAF V600E mutation testing (if not already done)
3. Send for MAP2K1 / MAPK pathway mutation panel if BRAF negative

Why: ~55% of LCH carries BRAF V600E. This single result determines whether Raj gets conventional salvage chemotherapy or goes straight to targeted therapy. This is the most important investigation right now.

STEP 2 — Molecular Workup (Simultaneous)

STEP 3 — Treatment Decision (Based on BRAF Result)

• Vemurafenib or Dabrafenib (± trametinib as combination)
• Response rates are remarkable even in heavily pretreated patients (per Abla 2023, PMID 38066856 and Lin & Cao 2024, PMID 38990463)
• However, relapse on discontinuation is near-universal — meaning he will likely need long-term or continuous therapy
• Emerging: Day 101 (tovorafenib) — a new panRAF inhibitor with promising results in R/R LCH

• Cobimetinib (MEK inhibitor) — FDA-approved for histiocytic neoplasms without BRAF V600E
• Also consider trametinib or binimetinib

• Cladribine (2-CdA) — first choice for relapsed LCH, ORR ~80%
• Cladribine + Cytarabine (CLARAC) — combination for more aggressive relapse
• Cytarabine alone (high-dose)
• Clofarabine — third-line option

"Cladribine and high-dose cytarabine may be effective in relapsed/refractory settings."

STEP 4 — Local Therapy for Dominant Lesion

• Low-dose involved-field radiotherapy (6–10 Gy) to the right frontal lesion if soft tissue extension is threatening neurovascular structures or causing pain
• Radiation is appropriate as a bridge to systemic therapy or as adjunct — not as sole treatment given multifocal disease

STEP 5 — Special Monitoring for Raj's DI

• Monitor serum sodium daily during chemotherapy infusions — use only isotonic (normal saline-based) IV fluids
• Avoid agents that cause SIADH (e.g., vincristine) if possible, or monitor sodium aggressively if used
• Continue DDAVP at current dose — do not adjust empirically during chemotherapy without sodium guidance
• Check morning urine osmolality and serum osmolality at each cycle start

Summary Flowchart

PET-CT: Post-chemo reactivation confirmed
         ↓
URGENT: Biopsy (rib or parietal lesion)
         ↓
BRAF V600E testing on tissue + cfDNA
         ↓
       POSITIVE                    NEGATIVE
          ↓                           ↓
  Vemurafenib/Dabrafenib      Cobimetinib (MEK inhibitor)
  ± Trametinib                or Cladribine ± Cytarabine
          ↓                           ↓
  Consider local RT to         Consider local RT to
  right frontal (SUV 16.1)     right frontal (SUV 16.1)
          ↓
  Continue DDAVP + close Na+ monitoring throughout

Bottom Line